25 XP   0   0   10

GlobeImmune Inc
Buy, Hold or Sell?

Let's analyse Globeimmune together

PenkeI guess you are interested in GlobeImmune Inc. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of GlobeImmune Inc. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

You can find me behind Let's Analyse Together in the top-right of each section.

Get notifications about GlobeImmune Inc

I send you an email if I find something interesting about GlobeImmune Inc.

Quick analysis of Globeimmune (30 sec.)










What can you expect buying and holding a share of Globeimmune? (30 sec.)

How much money do you get?

How much money do you get?
$0.00
When do you have the money?
1 year
How often do you get paid?
0.0%

What is your share worth?

Current worth
$0.52
Expected worth in 1 year
$-1.30
How sure are you?
16.7%

+ What do you gain per year?

Total Gains per Share
$-1.82
Return On Investment
-909,349.3%

For what price can you sell your share?

Current Price per Share
$0.00
Expected price per share
$0.0002 - $0.0002
How sure are you?
50%

1. Valuation of Globeimmune (5 min.)




Live pricePrice per Share (EOD)

$0.00

Intrinsic Value Per Share

$4.71 - $13.55

Total Value Per Share

$5.23 - $14.07

2. Growth of Globeimmune (5 min.)




Is Globeimmune growing?

Current yearPrevious yearGrowGrow %
How rich?$2.9m$5.6m-$2.6m-87.5%

How much money is Globeimmune making?

Current yearPrevious yearGrowGrow %
Making money-$2.7m-$20.1m$17.3m628.3%
Net Profit Margin-42.8%-337.8%--

How much money comes from the company's main activities?

3. Financial Health of Globeimmune (5 min.)




4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  

What can you expect buying and holding a share of Globeimmune? (5 min.)

Welcome investor! Globeimmune's management wants to use your money to grow the business. In return you get a share of Globeimmune.

What can you expect buying and holding a share of Globeimmune?

First you should know what it really means to hold a share of Globeimmune. And how you can make/lose money.

Speculation

The Price per Share of Globeimmune is $0.0002. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Globeimmune.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Globeimmune, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is $0.52. Based on the TTM, the Book Value Change Per Share is $-0.45 per quarter. Based on the YOY, the Book Value Change Per Share is $35.63 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is $0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Globeimmune.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 $% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share
Usd Eps-0.48-240,534.6%-0.48-240,534.6%-4.07-2,037,254.8%-2.04-1,018,615.8%-2.13-1,063,160.4%
Usd Book Value Change Per Share-0.45-227,337.3%-0.45-227,337.3%35.6317,814,729.3%5.592,794,099.2%0.0943,298.3%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%
Usd Total Gains Per Share-0.45-227,337.3%-0.45-227,337.3%35.6317,814,729.3%5.592,794,099.2%0.0943,298.3%
Usd Price Per Share3.87-3.87-7.59-2.29-1.91-
Price to Earnings Ratio-8.04--8.04--1.86--1.98--1.65-
Price-to-Total Gains Ratio-8.51--8.51-0.21--4.15--4.15-
Price to Book Ratio7.45-7.45-7.79-3.05-2.54-
Price-to-Total Gains Ratio-8.51--8.51-0.21--4.15--4.15-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share0.0002
Number of shares5000000
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share-0.455.59
Usd Total Gains Per Share-0.455.59
Gains per Quarter (5000000 shares)-2,273,373.2527,940,991.58
Gains per Year (5000000 shares)-9,093,493.01111,763,966.31
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
10-9093493-90935030111763966111763956
20-18186986-181869960223527933223527922
30-27280479-272804890335291899335291888
40-36373972-363739820447055865447055854
50-45467465-454674750558819832558819820
60-54560958-545609680670583798670583786
70-63654451-636544610782347764782347752
80-72747944-727479540894111730894111718
90-81841437-81841447010058756971005875684
100-90934930-90934940011176396631117639650

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share0.01.00.00.0%0.03.00.00.0%0.05.00.00.0%0.06.00.00.0%0.06.00.00.0%
Book Value Change Per Share0.01.00.00.0%1.02.00.033.3%1.04.00.020.0%1.05.00.016.7%1.05.00.016.7%
Dividend per Share0.00.01.00.0%0.00.03.00.0%0.00.05.00.0%0.00.06.00.0%0.00.06.00.0%
Total Gains per Share0.01.00.00.0%1.02.00.033.3%1.04.00.020.0%1.05.00.016.7%1.05.00.016.7%

Fundamentals of Globeimmune

About GlobeImmune Inc

GlobeImmune, Inc., a biopharmaceutical company, focuses on developing therapeutic products for cancer and infectious diseases based on proprietary Tarmogen platform. Its product candidate includes GS-4774, which is in Phase 2 trials for the treatment of patients with chronically infected with hepatitis B virus, as well as with oral antiviral suppressive therapy. The company is also involved in developing GI-6301 for the treatment of cancers expressing the brachyury protein; and GI-6207 that is in Phase 2 clinical trials to treat medullary thyroid cancer. In addition, it is involved in developing GI-4000, which is in Phase 2b clinical trials for the treatment of resected pancreas cancer; and is in Phase 2 clinical trial to treat non-small cell lung cancer, as well as is in Phase 2 clinical trial for the treatment of colorectal cancer. Further, the company is involved in developing various other product candidates targeting various infectious diseases that are in preclinical development stage, which include GI-19000 to treat tuberculosis; GI-2010 for the treatment of human immunodeficiency virus; and GI-18000 for hepatitis D virus infection. It has strategic collaborations with Gilead Sciences, Inc. and Celgene Corporation. The company was formerly known as Ceres Pharmaceuticals, Inc. and changed its name to GlobeImmune, Inc. in May 2001. GlobeImmune, Inc. was founded in 1995 and is headquartered in Louisville, Colorado. GlobeImmune, Inc. operates as a subsidiary of ImmunityBio, Inc.

Fundamental data was last updated by Penke on 2024-05-16 16:19:04.

Financial Health

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge loss.
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating very inefficient.
The company is inefficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is able to pay all its short-term debts.
The company is very able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is able to pay all its debts by selling its assets.
The company is unable to pay all its debts with equity.

Valuation

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is overpriced.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.

1.1. Profitability of GlobeImmune Inc.

1.1. Profitability
1.1.1. Net Profit Margin

Measures how much net profit Globeimmune earns for each $1 of revenue.

  • Above 10% is considered healthy but always compare Globeimmune to the Biotechnology industry mean.
  • A Net Profit Margin of -42.8% means that $-0.43 for each $1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of GlobeImmune Inc:

  • The MRQ is -42.8%. The company is making a huge loss. -2
  • The TTM is -42.8%. The company is making a huge loss. -2
Trends
Current periodCompared to+/- 
MRQ-42.8%TTM-42.8%0.0%
TTM-42.8%YOY-337.8%+294.9%
TTM-42.8%5Y-128.6%+85.8%
5Y-128.6%10Y-167.8%+39.2%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-42.8%-171.8%+129.0%
TTM-42.8%-211.9%+169.1%
YOY-337.8%-263.3%-74.5%
5Y-128.6%-414.0%+285.4%
10Y-167.8%-552.3%+384.5%
1.1.2. Return on Assets

Shows how efficient Globeimmune is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Globeimmune to the Biotechnology industry mean.
  • -24.0% Return on Assets means that Globeimmune generated $-0.24 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of GlobeImmune Inc:

  • The MRQ is -24.0%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -24.0%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-24.0%TTM-24.0%0.0%
TTM-24.0%YOY-109.7%+85.7%
TTM-24.0%5Y-27.4%+3.4%
5Y-27.4%10Y-33.3%+5.8%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-24.0%-11.9%-12.1%
TTM-24.0%-11.5%-12.5%
YOY-109.7%-10.9%-98.8%
5Y-27.4%-13.1%-14.3%
10Y-33.3%-14.4%-18.9%
1.1.3. Return on Equity

Shows how efficient Globeimmune is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Globeimmune to the Biotechnology industry mean.
  • -92.6% Return on Equity means Globeimmune generated $-0.93 for each $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of GlobeImmune Inc:

  • The MRQ is -92.6%. Using its investors money, the company is very inefficient in making profit. -2
  • The TTM is -92.6%. Using its investors money, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-92.6%TTM-92.6%0.0%
TTM-92.6%YOY-359.6%+267.0%
TTM-92.6%5Y-90.4%-2.1%
5Y-90.4%10Y-75.4%-15.1%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-92.6%-15.3%-77.3%
TTM-92.6%-14.6%-78.0%
YOY-359.6%-13.6%-346.0%
5Y-90.4%-17.7%-72.7%
10Y-75.4%-19.2%-56.2%

1.2. Operating Efficiency of GlobeImmune Inc.

1.2. Operating Efficiency
1.2.1. Operating Margin

Measures how efficient Globeimmune is operating .

  • Measures how much profit Globeimmune makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Globeimmune to the Biotechnology industry mean.
  • An Operating Margin of -42.8% means the company generated $-0.43  for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of GlobeImmune Inc:

  • The MRQ is -42.8%. The company is operating very inefficient. -2
  • The TTM is -42.8%. The company is operating very inefficient. -2
Trends
Current periodCompared to+/- 
MRQ-42.8%TTM-42.8%0.0%
TTM-42.8%YOY-97.5%+54.7%
TTM-42.8%5Y-76.0%+33.1%
5Y-76.0%10Y-131.8%+55.8%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-42.8%-336.0%+293.2%
TTM-42.8%-224.0%+181.2%
YOY-97.5%-280.1%+182.6%
5Y-76.0%-412.2%+336.2%
10Y-131.8%-521.7%+389.9%
1.2.2. Operating Ratio

Measures how efficient Globeimmune is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Biotechnology industry mean).
  • An Operation Ratio of 1.84 means that the operating costs are $1.84 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of GlobeImmune Inc:

  • The MRQ is 1.839. The company is inefficient in keeping operating costs low. -1
  • The TTM is 1.839. The company is inefficient in keeping operating costs low. -1
Trends
Current periodCompared to+/- 
MRQ1.839TTM1.8390.000
TTM1.839YOY2.812-0.974
TTM1.8395Y2.226-0.388
5Y2.22610Y2.667-0.441
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ1.8393.005-1.166
TTM1.8393.247-1.408
YOY2.8123.619-0.807
5Y2.2265.262-3.036
10Y2.6676.874-4.207

1.3. Liquidity of GlobeImmune Inc.

1.3. Liquidity
1.3.1. Current Ratio

Measures if Globeimmune is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Biotechnology industry mean).
  • A Current Ratio of 2.62 means the company has $2.62 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of GlobeImmune Inc:

  • The MRQ is 2.625. The company is able to pay all its short-term debts. +1
  • The TTM is 2.625. The company is able to pay all its short-term debts. +1
Trends
Current periodCompared to+/- 
MRQ2.625TTM2.6250.000
TTM2.625YOY3.444-0.819
TTM2.6255Y1.727+0.897
5Y1.72710Y1.978-0.250
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ2.6253.805-1.180
TTM2.6254.158-1.533
YOY3.4445.252-1.808
5Y1.7276.087-4.360
10Y1.9786.434-4.456
1.3.2. Quick Ratio

Measures if Globeimmune is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Globeimmune to the Biotechnology industry mean.
  • A Quick Ratio of 2.34 means the company can pay off $2.34 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of GlobeImmune Inc:

  • The MRQ is 2.343. The company is very able to pay all its short-term debts with the most liquid assets. +2
  • The TTM is 2.343. The company is very able to pay all its short-term debts with the most liquid assets. +2
Trends
Current periodCompared to+/- 
MRQ2.343TTM2.3430.000
TTM2.343YOY3.250-0.907
TTM2.3435Y1.577+0.766
5Y1.57710Y1.842-0.265
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ2.3433.202-0.859
TTM2.3433.816-1.473
YOY3.2505.183-1.933
5Y1.5775.929-4.352
10Y1.8426.351-4.509

1.4. Solvency of GlobeImmune Inc.

1.3. Liquidity
1.4.1. Debt to Asset Ratio

Measures how much % of Globeimmune assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Globeimmune to Biotechnology industry mean.
  • A Debt to Asset Ratio of 0.74 means that Globeimmune assets are financed with 74.0% credit (debt) and the remaining percentage (100% - 74.0%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of GlobeImmune Inc:

  • The MRQ is 0.740. The company is able to pay all its debts by selling its assets. +1
  • The TTM is 0.740. The company is able to pay all its debts by selling its assets. +1
Trends
Current periodCompared to+/- 
MRQ0.740TTM0.7400.000
TTM0.740YOY0.695+0.045
TTM0.7405Y17.565-16.825
5Y17.56510Y15.915+1.650
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.7400.344+0.396
TTM0.7400.342+0.398
YOY0.6950.279+0.416
5Y17.5650.366+17.199
10Y15.9150.380+15.535
1.4.2. Debt to Equity Ratio

Measures if Globeimmune is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Globeimmune to the Biotechnology industry mean.
  • A Debt to Equity ratio of 285.0% means that company has $2.85 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of GlobeImmune Inc:

  • The MRQ is 2.850. The company is unable to pay all its debts with equity. -1
  • The TTM is 2.850. The company is unable to pay all its debts with equity. -1
Trends
Current periodCompared to+/- 
MRQ2.850TTM2.8500.000
TTM2.850YOY2.278+0.572
TTM2.8505Y1.026+1.825
5Y1.02610Y0.855+0.171
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ2.8500.398+2.452
TTM2.8500.415+2.435
YOY2.2780.353+1.925
5Y1.0260.446+0.580
10Y0.8550.470+0.385

2. Market Valuation of GlobeImmune Inc

2.1. Earnings Per Share
2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every $1 in earnings Globeimmune generates.

  • Above 15 is considered overpriced but always compare Globeimmune to the Biotechnology industry mean.
  • A PE ratio of -8.04 means the investor is paying $-8.04 for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of GlobeImmune Inc:

  • The EOD is 0.000. Based on the earnings, the company is expensive. -2
  • The MRQ is -8.045. Based on the earnings, the company is expensive. -2
  • The TTM is -8.045. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD0.000MRQ-8.045+8.044
MRQ-8.045TTM-8.0450.000
TTM-8.045YOY-1.863-6.182
TTM-8.0455Y-1.981-6.063
5Y-1.98110Y-1.651-0.330
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD0.000-2.276+2.276
MRQ-8.045-2.535-5.510
TTM-8.045-2.723-5.322
YOY-1.863-3.942+2.079
5Y-1.981-6.316+4.335
10Y-1.651-6.544+4.893
2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of GlobeImmune Inc:

  • The EOD is 0.000. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -3.106. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is -3.106. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD0.000MRQ-3.106+3.106
MRQ-3.106TTM-3.1060.000
TTM-3.106YOY-4.220+1.113
TTM-3.1065Y-1.465-1.641
5Y-1.46510Y-1.221-0.244
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD0.000-3.153+3.153
MRQ-3.106-3.270+0.164
TTM-3.106-3.527+0.421
YOY-4.220-5.220+1.000
5Y-1.465-8.080+6.615
10Y-1.221-8.650+7.429
2. Book Value per Share
2.3. Price to Book Ratio

Measures if the stock price of Globeimmune is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Biotechnology industry mean).
  • A PB ratio of 7.45 means the investor is paying $7.45 for each $1 in book value.

Let's take a look of the Price to Book Ratio trends of GlobeImmune Inc:

  • The EOD is 0.000. Based on the equity, the company is cheap. +2
  • The MRQ is 7.448. Based on the equity, the company is overpriced. -1
  • The TTM is 7.448. Based on the equity, the company is overpriced. -1
Trends
Current periodCompared to+/- 
EOD0.000MRQ7.448-7.448
MRQ7.448TTM7.4480.000
TTM7.448YOY7.791-0.342
TTM7.4485Y3.048+4.401
5Y3.04810Y2.540+0.508
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD0.0002.066-2.066
MRQ7.4482.029+5.419
TTM7.4482.065+5.383
YOY7.7912.688+5.103
5Y3.0483.688-0.640
10Y2.5404.088-1.548
2. Total Gains per Share

3. Summary

3.1. Key Performance Indicators

The key performance indicators of GlobeImmune Inc compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share---0.455-0.4550%35.629-101%5.588-108%0.087-625%
Book Value Per Share--0.5200.5200%0.974-47%-19.795+3910%-21.066+4154%
Current Ratio--2.6252.6250%3.444-24%1.727+52%1.978+33%
Debt To Asset Ratio--0.7400.7400%0.695+7%17.565-96%15.915-95%
Debt To Equity Ratio--2.8502.8500%2.278+25%1.026+178%0.855+233%
Dividend Per Share----0%-0%-0%-0%
Eps---0.481-0.4810%-4.075+747%-2.037+323%-2.126+342%
Free Cash Flow Per Share---1.246-1.2460%-1.799+44%-1.109-11%-1.509+21%
Free Cash Flow To Equity Per Share---1.246-1.2460%1.871-167%-0.375-70%-0.378-70%
Gross Profit Margin--1.0001.0000%1.0000%1.0000%1.0000%
Intrinsic Value_10Y_max--13.554--------
Intrinsic Value_10Y_min--4.712--------
Intrinsic Value_1Y_max---0.326--------
Intrinsic Value_1Y_min---0.718--------
Intrinsic Value_3Y_max--0.305--------
Intrinsic Value_3Y_min---1.139--------
Intrinsic Value_5Y_max--2.482--------
Intrinsic Value_5Y_min---0.442--------
Market Cap1150.314-1934901%22258591.38022258591.3800%43654416.300-49%13182601.536+69%10985501.280+103%
Net Profit Margin---0.428-0.4280%-3.378+688%-1.286+200%-1.678+292%
Operating Margin---0.428-0.4280%-0.975+128%-0.760+77%-1.318+208%
Operating Ratio--1.8391.8390%2.812-35%2.226-17%2.667-31%
Pb Ratio0.000-1934900%7.4487.4480%7.791-4%3.048+144%2.540+193%
Pe Ratio0.000+100%-8.045-8.0450%-1.863-77%-1.981-75%-1.651-79%
Price Per Share0.000-1934900%3.8703.8700%7.590-49%2.292+69%1.910+103%
Price To Free Cash Flow Ratio0.000+100%-3.106-3.1060%-4.220+36%-1.465-53%-1.221-61%
Price To Total Gains Ratio0.000+100%-8.512-8.5120%0.213-4096%-4.149-51%-4.149-51%
Quick Ratio--2.3432.3430%3.250-28%1.577+49%1.842+27%
Return On Assets---0.240-0.2400%-1.097+356%-0.274+14%-0.333+38%
Return On Equity---0.926-0.9260%-3.596+288%-0.904-2%-0.754-19%
Total Gains Per Share---0.455-0.4550%35.629-101%5.588-108%0.087-625%
Usd Book Value--2988400.0002988400.0000%5603491.000-47%-113850297.600+3910%-121161276.500+4154%
Usd Book Value Change Per Share---0.455-0.4550%35.629-101%5.588-108%0.087-625%
Usd Book Value Per Share--0.5200.5200%0.974-47%-19.795+3910%-21.066+4154%
Usd Dividend Per Share----0%-0%-0%-0%
Usd Eps---0.481-0.4810%-4.075+747%-2.037+323%-2.126+342%
Usd Free Cash Flow---7165439.000-7165439.0000%-10345296.000+44%-6381177.800-11%-8678920.333+21%
Usd Free Cash Flow Per Share---1.246-1.2460%-1.799+44%-1.109-11%-1.509+21%
Usd Free Cash Flow To Equity Per Share---1.246-1.2460%1.871-167%-0.375-70%-0.378-70%
Usd Market Cap1150.314-1934901%22258591.38022258591.3800%43654416.300-49%13182601.536+69%10985501.280+103%
Usd Price Per Share0.000-1934900%3.8703.8700%7.590-49%2.292+69%1.910+103%
Usd Profit---2766905.000-2766905.0000%-20151588.000+628%-6062754.600+119%-7517578.333+172%
Usd Revenue--6457733.0006457733.0000%5966381.000+8%10938386.200-41%9793288.000-34%
Usd Total Gains Per Share---0.455-0.4550%35.629-101%5.588-108%0.087-625%
 EOD+3 -5MRQTTM+0 -0YOY+15 -185Y+18 -1510Y+21 -12

3.2. Fundamental Score

Let's check the fundamental score of GlobeImmune Inc based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-150.000
Price to Book Ratio (EOD)Between0-10.000
Net Profit Margin (MRQ)Greater than0-0.428
Operating Margin (MRQ)Greater than0-0.428
Quick Ratio (MRQ)Greater than12.343
Current Ratio (MRQ)Greater than12.625
Debt to Asset Ratio (MRQ)Less than10.740
Debt to Equity Ratio (MRQ)Less than12.850
Return on Equity (MRQ)Greater than0.15-0.926
Return on Assets (MRQ)Greater than0.05-0.240
Total4/10 (40.0%)

3.3. Technical Score

Let's check the technical score of GlobeImmune Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than500.000
Ma 20Greater thanMa 500.000
Ma 50Greater thanMa 1000.000
Ma 100Greater thanMa 2000.000
OpenGreater thanClose0.000
Total0/5 (0.0%)



Latest Balance Sheet

Balance Sheet of 2015-12-31. Currency in USD. All numbers in thousands.

Summary
Total Assets11,506
Total Liabilities8,518
Total Stockholder Equity2,988
 As reported
Total Liabilities 8,518
Total Stockholder Equity+ 2,988
Total Assets = 11,506

Assets

Total Assets11,506
Total Current Assets11,091
Long-term Assets415
Total Current Assets
Cash And Cash Equivalents 9,901
Other Current Assets 1,190
Total Current Assets  (as reported)11,091
Total Current Assets  (calculated)11,091
+/-0
Long-term Assets
Property Plant Equipment 210
Other Assets 206
Long-term Assets  (as reported)415
Long-term Assets  (calculated)415
+/-0

Liabilities & Shareholders' Equity

Total Current Liabilities4,225
Long-term Liabilities4,292
Total Stockholder Equity2,988
Total Current Liabilities
Accounts payable 234
Other Current Liabilities 541
Total Current Liabilities  (as reported)4,225
Total Current Liabilities  (calculated)775
+/- 3,451
Long-term Liabilities
Other Liabilities 4,292
Long-term Liabilities  (as reported)4,292
Long-term Liabilities  (calculated)4,292
+/-0
Total Stockholder Equity
Common Stock6
Retained Earnings -225,472
Other Stockholders Equity 228,454
Total Stockholder Equity (as reported)2,988
Total Stockholder Equity (calculated)2,988
+/-0
Other
Cash and Short Term Investments 9,901
Common Stock Shares Outstanding 5,752
Current Deferred Revenue3,451
Liabilities and Stockholders Equity 11,506
Net Debt -9,901
Net Tangible Assets 2,988
Net Working Capital 6,865



Balance Sheet

Currency in USD. All numbers in thousands.

 Trend2015-12-312014-12-312013-12-312012-12-312011-12-312010-12-31
> Total Assets 
23,672
17,745
4,241
7,418
18,368
11,506
11,50618,3687,4184,24117,74523,672
   > Total Current Assets 
20,684
15,577
2,889
6,825
17,812
11,091
11,09117,8126,8252,88915,57720,684
       Cash And Cash Equivalents 
20,291
15,155
2,003
5,924
16,812
9,901
9,90116,8125,9242,00315,15520,291
       Other Current Assets 
393
422
886
901
1,000
1,190
1,1901,000901886422393
   > Long-term Assets 
2,988
2,168
1,352
593
556
415
4155565931,3522,1682,988
       Property Plant Equipment 
2,888
2,068
1,252
493
456
210
2104564931,2522,0682,888
       Long-term Assets Other 
100
100
100
100
100
206
206100100100100100
> Total Liabilities 
181,388
200,142
200,366
206,740
12,765
8,518
8,51812,765206,740200,366200,142181,388
   > Total Current Liabilities 
6,403
13,442
8,351
6,414
5,172
4,225
4,2255,1726,4148,35113,4426,403
       Short-term Debt 
0
0
0
921
0
0
00921000
       Short Long Term Debt 
0
0
0
774,299
0
0
00774,299000
       Accounts payable 
1,133
1,315
2,957
1,737
573
234
2345731,7372,9571,3151,133
       Other Current Liabilities 
1,203
1,496
1,632
0
1,259
541
5411,25901,6321,4961,203
   > Long-term Liabilities 
174,985
186,699
192,015
200,325
7,592
4,292
4,2927,592200,325192,015186,699174,985
       Other Liabilities 
0
0
14,796
11,369
7,592
4,292
4,2927,59211,36914,79600
       Deferred Long Term Liability 
0
0
0
41,684,639
1,052,196
35,211
35,2111,052,19641,684,639000
> Total Stockholder Equity
-157,716
-182,397
-196,125
-199,322
5,603
2,988
2,9885,603-199,322-196,125-182,397-157,716
   Common Stock
3
3
0
0
6
6
660033
   Retained Earnings -225,472-222,705-199,322-196,125-182,399-157,719
   Accumulated Other Comprehensive Income -9,799-11,812-11,606-10,835-9,909-8,957
   Capital Surplus 000000
   Treasury Stock000000
   Other Stockholders Equity 
8,957
9,909
10,835
11,606
228,302
228,454
228,454228,30211,60610,8359,9098,957



Balance Sheet

Currency in USD. All numbers in thousands.




Cash Flow

Currency in USD. All numbers in thousands.




Income Statement

Currency in USD. All numbers in thousands.


Latest Income Statement (annual, 2015-12-31)

Gross Profit (+$)
totalRevenue6,458
Cost of Revenue-2,648
Gross Profit6,4583,810
 
Operating Income (+$)
Gross Profit6,458
Operating Expense-9,225
Operating Income-2,767-2,767
 
Operating Expense (+$)
Research Development4,483
Selling General Administrative4,554
Selling And Marketing Expenses0
Operating Expense9,2259,037
 
Net Interest Income (+$)
Interest Income0
Interest Expense-0
Other Finance Cost-0
Net Interest Income0
 
Pretax Income (+$)
Operating Income-2,767
Net Interest Income0
Other Non-Operating Income Expenses0
Income Before Tax (EBT)-2,767-2,767
EBIT - interestExpense = -2,767
-2,767
-2,767
Interest Expense0
Earnings Before Interest and Taxes (EBIT)-2,767-2,767
Earnings Before Interest and Taxes (EBITDA)-2,580
 
After tax Income (+$)
Income Before Tax-2,767
Tax Provision-0
Net Income From Continuing Ops-2,767-2,767
Net Income-2,767
Net Income Applicable To Common Shares-2,767
 
Non-recurring Events
Discontinued Operations0
Extraordinary Items0
Effect of Accounting Charges0
Other Items0
Non Recurring0
Other Operating Expenses9,225
Total Other Income/Expenses Net00
 

Technical Analysis of Globeimmune
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Globeimmune. The general trend of Globeimmune is BEARISH with 100.0% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Globeimmune's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (-100.0%) Bearish trend (100.0%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of GlobeImmune Inc.

The long score for the Support & Resistance is 1/1.
The longshort score for the Support & Resistance is 1/(-1 +1).

  • Around support: The price is currently trading around a support level. This can be considered as a potential entry level. +1

The bullish price targets are: 0.0002 < 0.0002 < 0.0002.

The bearish price targets are: 0.0002 > 0.0002 > 0.0002.

Tweet this
GlobeImmune Inc Daily Support & Resistance Chart

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of GlobeImmune Inc. The current mas is .

The long score for the Moving Averages is 0/14.
The longshort score for the Moving Averages is -14/(-14 +14).

  • MA 20 trending down: The MA 20 is trending down. -1
  • Close < MA 20: The price is below the MA 20. -1
  • MA 20 < MA 50: The MA 20 is lower than the MA 50. -1
  • MA 20 < MA 100: The MA 20 is lower than the MA 100. -1
  • MA 20 < MA 200: The MA 20 is lower than the MA 200. -1
  • MA 50 trending down: The MA 50 is trending down. -1
  • Close < MA 50: The price is below the MA 50. -1
  • MA 50 < MA 100: The MA 50 is lower than the MA 100. -1
  • MA 50 < MA 200: The MA 50 is lower than the MA 200. -1
  • MA 100 trending down: The MA 100 is trending down. -1
  • Close < MA 100: The price is below the MA 100. -1
  • MA 100 < MA 200: The MA 100 is lower than the MA 200. -1
  • MA 200 trending down: The MA 200 is trending down. -1
  • Close < MA 200: The price is below the MA 200. -1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

GlobeImmune Inc Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of GlobeImmune Inc. The current macd is 0.

The long score for the Moving Average Convergence/Divergence (MACD) is 0/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is -4/(-4 +4).

  • MACD line < signal line: The MACD line is below the signal line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Globeimmune price going down in the near term. -2
  • MACD < 0: The MACD is below the zero line (centerline), it indicates a bearish signal for Globeimmune. This means that the short-term moving average is lower than the long-term moving average, signaling negative momentum and suggesting a higher likelihood of the Globeimmune price continuing to fall in the near future. It indicates that sellers are gaining control, and there is negativism in the market, leading to potential price decreases. -1
  • Trending down: The MACD line is trending down. This indicates that the short-term moving average is falling faster than the long-term moving average, suggesting negative momentum in the market. This signals that sellers are becoming more active and insecure, leading to potential price decreases as traders anticipate further losses and are willing to sell at lower prices. -1
GlobeImmune Inc Daily Moving Average Convergence/Divergence (MACD) ChartGlobeImmune Inc Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of GlobeImmune Inc. The current adx is 12.11.

The long score for the Directional Movement Index (DMI) is 0/7.
The longshort score for the Directional Movement Index (DMI) is 0/(-7 +7).

  • PLUS_ID < MINUS_DI && ADX < 25 && ADX trending down: The ADX is below 25 and indicates a weak or no trend. Also, the ADX is declining so there is no trend indication.
GlobeImmune Inc Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of GlobeImmune Inc. The current sar is 0.00020003.

The long score for the Parabolic SAR is 0/1.
The longshort score for the Parabolic SAR is -1/(-1 +1).

  • Close < SAR: The price is below the SAR. It's generally considered a bearish signal. -1
GlobeImmune Inc Daily Parabolic SAR Chart

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of GlobeImmune Inc. The current rsi is 0. The current phase is Oversold in bear market.

The long score for the Relative Strength Index (RSI) is 1/13.
The longshort score for the Relative Strength Index (RSI) is 1/(-13 +13).

  • Oversold in bear market: Short-term excessive selling, potential for relief rally. Be cautious, consider taking short-term long positions. +1
GlobeImmune Inc Daily Relative Strength Index (RSI) ChartGlobeImmune Inc Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of GlobeImmune Inc. The current phase is Oversold in bear market.

The long score for the Stochastic Oscillator is 0/6.
The longshort score for the Stochastic Oscillator is -6/(-6 +6).

  • STOCH < 50: The STOCH %K is below 50. There are more sellers than buyers. -1
  • STOCH < 20: The STOCH %K is below 20 and oversold. -2
  • STOCH %K line < STOCH %D line: The STOCH %K line is below the STOCH %D line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Globeimmune price going down in the near term. -2
  • Trending down: The STOCH %K is trending down. -1
GlobeImmune Inc Daily Stochastic Oscillator ChartGlobeImmune Inc Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of GlobeImmune Inc. The current cci is -66.66666667.

GlobeImmune Inc Daily Commodity Channel Index (CCI) ChartGlobeImmune Inc Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of GlobeImmune Inc. The current cmo is 0.

GlobeImmune Inc Daily Chande Momentum Oscillator (CMO) ChartGlobeImmune Inc Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of GlobeImmune Inc. The current willr is 0.

The long score for the Williams %R is 1/1.
The longshort score for the Williams %R is 1/(-1 +1).

  • WILLR > -20: The Williams %R is above -20. This indicates that the price is in overbought territory, suggesting a potential price correction or trend reversal to the downside. +1
GlobeImmune Inc Daily Williams %R ChartGlobeImmune Inc Daily Williams %R Chart

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of GlobeImmune Inc.

GlobeImmune Inc Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of GlobeImmune Inc. The current atr is 0.

GlobeImmune Inc Daily Average True Range (ATR) ChartGlobeImmune Inc Daily Average True Range (ATR) Chart

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of GlobeImmune Inc. The current obv is 6,685.

GlobeImmune Inc Daily On-Balance Volume (OBV) ChartGlobeImmune Inc Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of GlobeImmune Inc. The current mfi is 0.

The long score for the Money Flow Index (MFI) is 0/2.
The longshort score for the Money Flow Index (MFI) is -2/(-2 +2).

  • MFI < 50: -1
  • MFI < 20: -1
GlobeImmune Inc Daily Money Flow Index (MFI) ChartGlobeImmune Inc Daily Money Flow Index (MFI) Chart

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for GlobeImmune Inc.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2024-01-03MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2024-01-24MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.

6.3. Candlestick Patterns

GlobeImmune Inc Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of GlobeImmune Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than500.000
Ma 20Greater thanMa 500.000
Ma 50Greater thanMa 1000.000
Ma 100Greater thanMa 2000.000
OpenGreater thanClose0.000
Total0/5 (0.0%)
Penke

Good job! You gained 25 XP and 0   0   10 . What's next:

  • Share my analysis of Globeimmune with someone you think should read this too:
  • Are you bullish or bearish on Globeimmune? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Globeimmune? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about GlobeImmune Inc

I send you an email if I find something interesting about GlobeImmune Inc.


Comments

How you think about this?

Leave a comment

Stay informed about GlobeImmune Inc.

Receive notifications about GlobeImmune Inc in your mailbox!